This Article Full Text Full Text (PDF) All Versions of this Article: 90/10/5677    most recent Author Manuscript (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Lawlor, D. A. Articles by Sattar, N. Search for Related Content PubMed PubMed Citation Articles by Lawlor, D. A. Articles by Sattar, N. Related Collections Cardiovascular Endocrinology Metabolism Obesity

Plasma Adiponectin Levels Are Associated with Insulin Resistance, But Do Not Predict Future Risk of Coronary Heart Disease in Women

Department of Social Medicine, University of Bristol (D.A.L., G.D.S., S.E.), Bristol BS8 2PR, United Kingdom; and Division of Cardiovascular and Medical Sciences, University of Glasgow (C.T., N.S.), Glasgow G31 2ER, Scotland, United Kingdom

Address all correspondence and requests for reprints to: Dr. Debbie A. Lawlor, Department of Social Medicine, University of Bristol, Canynge Hall, Whiteladies Road, Bristol BS8 2PR, United Kingdom. E-mail: d.a.lawlor{at}bristol.ac.uk.

Context: Low adiponectin levels predict type 2 diabetes, and one prospective study in men reported its independent prediction of vascular events. Many observers thus already consider adiponectin to be a major part of the "common soil" underpinning diabetes and vascular disease.

Objective: The objective of this study was to assess the association between adiponectin and incident coronary heart disease (CHD) risk in the British Women’s Heart and Health Study.

Design: This was a prospective (4 yr) case (n = 167) control (n = 334) study nested within the 4286 women in British Women’s Heart and Health Study.

Setting: The study was performed in a primary care setting.

Participants: The study consisted of women (n = 4286) randomly selected from 23 British towns between 1999 and 2001, who were 60–79 yr of age at baseline.

Main Outcome Measures: Association of adiponectin with CHD risk factors and incident CHD events were the main outcome measures.

Results: Among both cases and controls, adiponectin positively correlated with age and high-density lipoprotein cholesterol and inversely correlated with waist to hip ratio, fasting insulin, fasting glucose, homeostasis model assessment of insulin resistance scores, C-reactive protein, and triglycerides. However, despite adequate power and these associations with CHD risk factors, adiponectin did not predict CHD events in unadjusted or adjusted analyses. The relative risk ratio for a doubling of adiponectin was 0.93 (95% confidence interval, 0.78, 1.11).

Conclusions: It is premature to consider adiponectin as a root for vascular disease in women despite its association with insulin resistance and diabetes. Additional prospective studies are required to determine whether there is a true sex difference in the effect of adiponectin on CHD.

This article has been cited by other articles:

				J. R. Kizer, J. I. Barzilay, L. H. Kuller, and J. S. Gottdiener Adiponectin and Risk of Coronary Heart Disease in Older Men and Women J. Clin. Endocrinol. Metab., September 1, 2008; 93(9): 3357 - 3364. [Abstract] [Full Text] [PDF]

				G. Maiolino, M. Cesari, D. Sticchi, M. Zanchetta, L. Pedon, K. Antezza, A. C. Pessina, and G. P. Rossi Plasma Adiponectin for Prediction of Cardiovascular Events and Mortality in High-Risk Patients J. Clin. Endocrinol. Metab., September 1, 2008; 93(9): 3333 - 3340. [Abstract] [Full Text] [PDF]

				M. Rao, L. Li, H. Tighiouart, B. L. Jaber, B. J. G. Pereira, V. S. Balakrishnan, and the HEMO Study Group Plasma adiponectin levels and clinical outcomes among haemodialysis patients Nephrol. Dial. Transplant., August 1, 2008; 23(8): 2619 - 2628. [Abstract] [Full Text] [PDF]

				A. Qasim, N. N. Mehta, M. G. Tadesse, M. L. Wolfe, T. Rhodes, C. Girman, and M. P. Reilly Adipokines, insulin resistance, and coronary artery calcification. J. Am. Coll. Cardiol., July 15, 2008; 52(3): 231 - 236. [Abstract] [Full Text] [PDF]

				M. Karmazyn, D. M. Purdham, V. Rajapurohitam, and A. Zeidan Signalling mechanisms underlying the metabolic and other effects of adipokines on the heart Cardiovasc Res, July 15, 2008; 79(2): 279 - 286. [Abstract] [Full Text] [PDF]

				M. von Eynatten, A. Hamann, D. Twardella, P. P. Nawroth, H. Brenner, and D. Rothenbacher Atherogenic dyslipidaemia but not total- and high-molecular weight adiponectin are associated with the prognostic outcome in patients with coronary heart disease Eur. Heart J., May 2, 2008; 29(10): 1307 - 1315. [Abstract] [Full Text] [PDF]

				J.-P. Empana Adiponectin isoforms and cardiovascular disease: the epidemiological evidence has just begun Eur. Heart J., May 2, 2008; 29(10): 1221 - 1223. [Full Text] [PDF]

				N. Sattar, P. Watt, L. Cherry, S. Ebrahim, G. Davey Smith, and D. A. Lawlor High Molecular Weight Adiponectin Is Not Associated with Incident Coronary Heart Disease in Older Women: A Nested Prospective Case-Control Study J. Clin. Endocrinol. Metab., May 1, 2008; 93(5): 1846 - 1849. [Abstract] [Full Text] [PDF]

				S. P. Marso, S. K. Mehta, A. Frutkin, J. A. House, J. R. McCrary, and K. R. Kulkarni Low Adiponectin Levels Are Associated With Atherogenic Dyslipidemia and Lipid-Rich Plaque in Nondiabetic Coronary Arteries Diabetes Care, May 1, 2008; 31(5): 989 - 994. [Abstract] [Full Text] [PDF]

				J. M. Dekker, T. Funahashi, G. Nijpels, S. Pilz, C. D. A. Stehouwer, M. B. Snijder, L. M. Bouter, Y. Matsuzawa, I. Shimomura, and R. J. Heine Prognostic Value of Adiponectin for Cardiovascular Disease and Mortality J. Clin. Endocrinol. Metab., April 1, 2008; 93(4): 1489 - 1496. [Abstract] [Full Text] [PDF]

				R. Schnabel, C. M. Messow, E. Lubos, C. Espinola-Klein, H. J. Rupprecht, C. Bickel, C. Sinning, S. Tzikas, T. Keller, S. Genth-Zotz, et al. Association of adiponectin with adverse outcome in coronary artery disease patients: results from the AtheroGene study Eur. Heart J., March 1, 2008; 29(5): 649 - 657. [Abstract] [Full Text] [PDF]

				M. Matsumoto, S. Ishikawa, and E. Kajii Association of Adiponectin With Cerebrovascular Disease: A Nested Case-Control Study Stroke, February 1, 2008; 39(2): 323 - 328. [Abstract] [Full Text] [PDF]

				G. D. Lopaschuk, C. D.L. Folmes, and W. C. Stanley Cardiac Energy Metabolism in Obesity Circ. Res., August 17, 2007; 101(4): 335 - 347. [Abstract] [Full Text] [PDF]

				S. G. Wannamethee, P. H. Whincup, L. Lennon, and N. Sattar Circulating Adiponectin Levels and Mortality in Elderly Men With and Without Cardiovascular Disease and Heart Failure Arch Intern Med, July 23, 2007; 167(14): 1510 - 1517. [Abstract] [Full Text] [PDF]

				A. J. G. Hanley, D. Bowden, L. E. Wagenknecht, A. Balasubramanyam, C. Langfeld, M. F. Saad, J. I. Rotter, X. Guo, Y.-D. I. Chen, M. Bryer-Ash, et al. Associations of Adiponectin with Body Fat Distribution and Insulin Sensitivity in Nondiabetic Hispanics and African-Americans J. Clin. Endocrinol. Metab., July 1, 2007; 92(7): 2665 - 2671. [Abstract] [Full Text] [PDF]

				R. Shibata, K. Sato, M. Kumada, Y. Izumiya, M. Sonoda, S. Kihara, N. Ouchi, and K. Walsh Adiponectin accumulates in myocardial tissue that has been damaged by ischemia-reperfusion injury via leakage from the vascular compartment Cardiovasc Res, June 1, 2007; 74(3): 471 - 479. [Abstract] [Full Text] [PDF]

				T. A. Hopkins, N. Ouchi, R. Shibata, and K. Walsh Adiponectin actions in the cardiovascular system Cardiovasc Res, April 1, 2007; 74(1): 11 - 18. [Abstract] [Full Text] [PDF]

				T. Pischon, M. B. Schulze, and E. B. Rimm Letter by Pischon et al Regarding Article, "Adiponectin and Coronary Heart Disease: A Prospective Study and Meta-Analysis" Circulation, March 13, 2007; 115(10): e322 - e322. [Full Text] [PDF]

				N. Sattar, L. Cherry, A. M. Wallace, G. Wannamethee, J. Tchernova, N. Sarwar, J. Danesh, and P. H. Whincup Response to Letter Regarding Article, "Adiponectin and Coronary Heart Disease: A Prospective Study and Meta-Analysis" Circulation, March 13, 2007; 115(10): e323 - e323. [Full Text] [PDF]

				S. H. Han, M. J. Quon, J.-a Kim, and K. K. Koh Adiponectin and Cardiovascular Disease: Response to Therapeutic Interventions J. Am. Coll. Cardiol., February 6, 2007; 49(5): 531 - 538. [Abstract] [Full Text] [PDF]

				J. Lin, F. B. Hu, and G. Curhan Serum Adiponectin and Renal Dysfunction in Men With Type 2 Diabetes Diabetes Care, February 1, 2007; 30(2): 239 - 244. [Abstract] [Full Text] [PDF]

				J. Frystyk, C. Berne, L. Berglund, K. Jensevik, A. Flyvbjerg, and B. Zethelius Serum Adiponectin Is a Predictor of Coronary Heart Disease: A Population-Based 10-Year Follow-Up Study in Elderly Men J. Clin. Endocrinol. Metab., February 1, 2007; 92(2): 571 - 576. [Abstract] [Full Text] [PDF]

				G. A. Laughlin, E. Barrett-Connor, S. May, and C. Langenberg Association of Adiponectin with Coronary Heart Disease and Mortality: The Rancho Bernardo Study Am. J. Epidemiol., January 15, 2007; 165(2): 164 - 174. [Abstract] [Full Text] [PDF]

				A. M. Kanaya, C. Wassel Fyr, E. Vittinghoff, P. J. Havel, M. Cesari, B. Nicklas, T. Harris, A. B. Newman, S. Satterfield, S. R. Cummings, et al. Serum Adiponectin and Coronary Heart Disease Risk in Older Black and White Americans J. Clin. Endocrinol. Metab., December 1, 2006; 91(12): 5044 - 5050. [Abstract] [Full Text] [PDF]

				S. Pilz, H. Mangge, B. Wellnitz, U. Seelhorst, B. R. Winkelmann, B. Tiran, B. O. Boehm, and W. Marz Adiponectin and Mortality in Patients Undergoing Coronary Angiography J. Clin. Endocrinol. Metab., November 1, 2006; 91(11): 4277 - 4286. [Abstract] [Full Text] [PDF]

				V. Menon, L. Li, X. Wang, T. Greene, V. Balakrishnan, M. Madero, A. A. Pereira, G. J. Beck, J. W. Kusek, A. J. Collins, et al. Adiponectin and Mortality in Patients with Chronic Kidney Disease J. Am. Soc. Nephrol., September 1, 2006; 17(9): 2599 - 2606. [Abstract] [Full Text] [PDF]

				N. Sattar, G. Wannamethee, N. Sarwar, J. Tchernova, L. Cherry, A. M. Wallace, J. Danesh, and P. H. Whincup Adiponectin and Coronary Heart Disease: A Prospective Study and Meta-Analysis Circulation, August 15, 2006; 114(7): 623 - 629. [Abstract] [Full Text] [PDF]

				B. Iglseder, G. Ladurner, V. Mackevics, A. Stadlmayer, B. Paulweber, and G. Tasch Response to Letter by Pilz et al Stroke, July 1, 2006; 37(7): 1643 - 1643. [Full Text] [PDF]

				T. Pischon and E. B. Rimm Adiponectin: a promising marker for cardiovascular disease. Clin. Chem., May 1, 2006; 52(5): 797 - 799. [Full Text] [PDF]

				M. von Eynatten, A. Hamann, D. Twardella, P. P. Nawroth, H. Brenner, and D. Rothenbacher Relationship of Adiponectin with Markers of Systemic Inflammation, Atherogenic Dyslipidemia, and Heart Failure in Patients with Coronary Heart Disease Clin. Chem., May 1, 2006; 52(5): 853 - 859. [Abstract] [Full Text] [PDF]